President Donald Trump, after previously sparing the pharmaceutical sector in his trade disputes, is now reconsidering his stance. On April 8, he revealed intentions to implement a significant tariff on pharmaceutical imports, a decision that could greatly impact India’s robust pharmaceutical industry, which is heavily dependent on trade with the United States. Previously, pharmaceuticals and semiconductors were exempt from his “beautiful” reciprocal tariff strategy, but this recent development indicates a shift in his policy approach. During a National Republican Congressional Committee event, Trump articulated that the new tariffs aim to encourage pharmaceutical companies to move their operations back to the U.S. The United States represents the largest market for India’s pharmaceutical exports.
In the fiscal year 2024, India exported $8.7 billion in pharmaceutical products to the U.S., accounting for 31% of its total pharmaceutical exports, which reached $27.9 billion. India supplies over 45% of the generics and 15% of the biosimilars utilized in the U.S., with prominent companies such as Dr. Reddy’s, Aurobindo Pharma, Zydus Lifesciences, Sun Pharma, and Gland Pharma deriving up to 50% of their total revenue from the American market. Experts caution that the introduction of higher tariffs could have adverse effects for both nations. In the U.S., it may lead to increased production costs for manufacturers, diminish price competitiveness, and elevate drug prices. The U.S. relies on affordable generics from India, and higher tariffs could result in inflation, price increases, and even potential drug shortages. Indian firms, which operate on narrow margins in the generics sector, may find it challenging to absorb the additional costs, ultimately passing them on to U.S. consumers or insurers. Several major Indian pharmaceutical companies are significantly dependent on the U.S. market. For instance, Sun Pharmaceutical, the largest drug manufacturer in India, reported that 32% of its revenue in 2024 came from the U.S., with managing director Dilip Shanghvi acknowledging that the increased costs would likely be transferred to consumers.
